Neovasc Reducer Featured In FOCUS Magazine
Posted on November 26, 2019 by Medtech[y] Staff
Neovasc, Inc. (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that the Neovasc Reducer (the "Reducer") was featured in a supplement in the FOCUS Magazine, one of the three most widely circulated weekly news magazines in Germany.
Professor Tommaso Gori, who leads the cardiac catheterization lab at the prestigious University Hospital Mainz, explained to FOCUS readers in the supplement called “Medizinischer Fortschritt” how Reducer therapy helps patients with Chronic Angina Pectoris. Professor Gori commented on the available robust clinical evidence on the safety and efficacy of the Reducer therapy and highlighted that 75% of patients treated with Reducer feel better and experience less chest pain.
Fred Colen, President and Chief Executive Officer of Neovasc, stated, “The entire team at Neovasc is extremely proud to have Professor Gori present the Reducer therapy in such a well known and highly informative magazine. With the Reducer added to the European Society of Cardiology Practice Guidelines at the highest recommendation class for therapies addressing refractory angina, we thank Professor Gori for educating a very broad audience on the benefits of the Reducer and its ability to provide a treatment option for patients with an unmet medical need in Germany.”
About Neovasc Inc.
Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include the Reducer™, for the treatment of refractory angina, which is not currently commercially available in the United States (2 US patients have been treated under Compassionate Use) and has been commercially available in Europe since 2015, and Tiara™, for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada, Israel and Europe. For more information, visit: www.neovasc.com.